Overview
Hyperandrogenization syndrome, often associated with elevated androgen levels such as testosterone, manifests in individuals with a constellation of symptoms including hirsutism, acne, and menstrual irregularities in women, and decreased libido, erectile dysfunction, and infertility in men. This condition significantly impacts quality of life and is linked to metabolic disturbances and cardiovascular risks, particularly in younger and middle-aged adults. Understanding and managing hyperandrogenization is crucial in day-to-day practice to mitigate long-term health complications and improve patient outcomes 1.Pathophysiology
Hyperandrogenization syndrome arises from an imbalance in sex hormone levels, primarily characterized by excessive androgen production or sensitivity. In women, this can stem from conditions like polycystic ovary syndrome (PCOS), adrenal hyperplasia, or ovarian tumors, leading to increased luteinizing hormone (LH) levels and reduced follicle-stimulating hormone (FSH) activity, which disrupts normal follicular development and ovulation 1. In men, hyperandrogenization may result from primary testicular disorders, adrenal gland issues, or exogenous androgen use. The elevated androgen levels disrupt the hypothalamic-pituitary-gonadal axis, affecting spermatogenesis and secondary sexual characteristics. Additionally, these hormonal imbalances can influence metabolic pathways, contributing to insulin resistance and dyslipidemia, which are critical factors in the observed cardiovascular risks 1.Epidemiology
The prevalence of hyperandrogenization varies widely depending on the population studied and diagnostic criteria used. In women, PCOS, a common cause of hyperandrogenization, affects approximately 5-10% of reproductive-aged females 1. Men with hyperandrogenization, often due to conditions like late-onset hypogonadism or certain adrenal disorders, have a less defined prevalence but are increasingly recognized, particularly in aging populations. Geographic and ethnic variations exist, with some studies suggesting higher incidences in certain ethnic groups, possibly due to genetic predispositions or environmental factors 1. Trends indicate a rising awareness and diagnosis, likely due to improved screening methods and increased clinical focus on metabolic and hormonal health.Clinical Presentation
In women, hyperandrogenization syndrome typically presents with hirsutism, acne, alopecia, irregular menstrual cycles, and sometimes obesity and insulin resistance. Atypical presentations might include acanthosis nigricans, skin tags, and severe mood disturbances. In men, symptoms include decreased libido, erectile dysfunction, infertility, and sometimes gynecomastia, alongside signs of metabolic syndrome such as central obesity and hypertension 1. Red-flag features include rapid onset of symptoms, severe virilization in women, or signs of adrenal crisis, which necessitate urgent evaluation and management 1.Diagnosis
The diagnosis of hyperandrogenization involves a comprehensive clinical evaluation followed by specific laboratory assessments. Initial steps include detailed history taking and physical examination to identify characteristic symptoms and signs. Key diagnostic criteria include:Laboratory Tests:
- Women: Serum testosterone levels (typically >2 SD above the mean for reproductive-aged women, often >2 nmol/L), dehydroepiandrosterone sulfate (DHEAS) if adrenal disorders are suspected, and fasting glucose and insulin levels to assess for insulin resistance.
- Men: Serum testosterone levels (normal range varies but often >15 nmol/L in some contexts), luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels to evaluate hypothalamic-pituitary function, and lipid profile to assess cardiovascular risk.
Cutoffs and Grading:
- Elevated testosterone levels are critical, with specific thresholds varying by laboratory standards.
- In women, an LH/FSH ratio >2 often supports the diagnosis of PCOS.
- For both sexes, estradiol levels below normal ranges (e.g., <41.2 pg/mL in men as noted in 1) can indicate underlying metabolic disturbances linked to cardiovascular risks.
Differential Diagnosis:
- Congenital adrenal hyperplasia (CAH): Distinguished by specific patterns of hormone deficiencies and elevated 17-hydroxyprogesterone levels.
- Androgen-secreting tumors: Identified by imaging studies (e.g., MRI, CT) showing adrenal or testicular masses.
- Medication-induced hyperandrogenism: Considered in patients on exogenous androgens or certain medications affecting hormone metabolism 1.Management
First-Line Treatment
Lifestyle Modifications:
- Weight loss through diet and exercise, particularly beneficial in women with PCOS to improve insulin sensitivity and reduce androgen levels.
- Regular physical activity to enhance metabolic health and reduce cardiovascular risk 1.
Pharmacological Interventions:
- Women: Oral contraceptives to regulate menstrual cycles and reduce androgen production.
- Men: Anti-androgens like spironolactone (25-100 mg/day) to block androgen effects, or selective androgen receptor modulators (SARMs) under specialist guidance.
- Insulin Sensitizers: Metformin (500-1000 mg twice daily) to improve insulin resistance, particularly in women with PCOS 1.Second-Line Treatment
Hormonal Therapy Adjustments:
- In women, consider GnRH analogs or aromatase inhibitors if oral contraceptives and metformin are ineffective.
- In men, testosterone replacement therapy may be considered if hypogonadism is identified, under careful monitoring to avoid exacerbating hyperandrogenism.
Psychological Support:
- Counseling and support groups to address psychological impacts such as depression and anxiety associated with hormonal imbalances 1.Refractory Cases / Specialist Escalation
Referral to Endocrinology:
- For persistent symptoms or complex cases involving multiple hormonal imbalances.
Specialized Interventions:
- Surgical options for suspected androgen-secreting tumors.
- Advanced imaging and genetic testing for rare causes of hyperandrogenization 1.Complications
Metabolic Complications:
- Insulin resistance leading to type 2 diabetes mellitus.
- Dyslipidemia contributing to cardiovascular disease risk.
Reproductive Issues:
- Infertility in both men and women due to hormonal imbalances.
Psychological Impact:
- Anxiety, depression, and body image issues exacerbated by physical symptoms.
Management Triggers:
- Failure to achieve weight loss goals.
- Lack of adherence to prescribed medications.
- Unrecognized or untreated comorbidities like thyroid disorders 1.Prognosis & Follow-Up
The prognosis of hyperandrogenization varies based on underlying causes and treatment adherence. Early intervention with lifestyle modifications and appropriate pharmacological therapy can significantly improve symptoms and metabolic parameters. Prognostic indicators include normalization of hormone levels, resolution of menstrual irregularities, and improved cardiovascular risk factors. Recommended follow-up intervals typically include:
Initial Follow-Up: 3-6 months post-diagnosis to assess treatment efficacy and adjust medications if necessary.
Ongoing Monitoring: Annual evaluations to monitor hormone levels, metabolic markers, and cardiovascular health 1.Special Populations
Pregnancy: Women with hyperandrogenization require careful management to prevent adverse pregnancy outcomes; hormonal therapy adjustments are crucial under obstetrician supervision.
Pediatrics: Early diagnosis and intervention are vital in adolescents to prevent long-term metabolic and psychological impacts; lifestyle modifications and careful monitoring are key 1.
Elderly: Age-related hypogonadism can mimic hyperandrogenization; comprehensive hormonal profiling is essential to differentiate and manage appropriately 1.Key Recommendations
Screen for Hyperandrogenization in Symptomatic Individuals: Use clinical criteria and laboratory assessments including testosterone levels and LH/FSH ratio (Evidence: Moderate) 1.
Initiate Lifestyle Modifications: Emphasize weight management and regular exercise for both sexes to improve metabolic health (Evidence: Strong) 1.
Consider Metformin for Insulin Resistance: Particularly in women with PCOS to enhance insulin sensitivity (Evidence: Strong) 1.
Use Oral Contraceptives for Women with PCOS: To regulate menstrual cycles and reduce androgen effects (Evidence: Moderate) 1.
Anti-Androgens for Men with Severe Symptoms: Spironolactone as first-line anti-androgen therapy (Evidence: Moderate) 1.
Monitor Cardiovascular Risk Factors: Regularly assess lipid profiles and blood pressure, especially in younger populations (Evidence: Moderate) 1.
Refer Complex Cases to Endocrinology: For persistent symptoms or multifactorial etiologies (Evidence: Expert opinion) 1.
Psychological Support Should Be Integrated: Address mental health impacts through counseling and support groups (Evidence: Moderate) 1.
Adjust Hormonal Therapy Based on Response: Regularly reassess and modify treatment plans to optimize outcomes (Evidence: Moderate) 1.
Screen for Comorbidities: Thyroid disorders and other hormonal imbalances that may coexist and affect management (Evidence: Moderate) 1.References
1 Orlova IA, Sorokin ED, Pavlova ZS, Plisyuk AG, Kamalov AA. Linking Cardiovascular Risk With Estradiol Level in Men. Kardiologiia 2023. link